Van Campen Liem assisted Prilenia Therapeutics in its $62.5M Series A Funding Round. The clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders will use the raised funding to launch the company’s two late-stage clinical trials of pridopidine in Huntington Disease (HD) and Amyotrophic Lateral Sclerosis (ALS).
The Series A round was led by Forbion, and accompanied by Morningside Venture Investments, Sectoral Asset Management, Talisman Capital Ventures and Genworks 2. The Series A financing brings the total capital investment in Prilenia Therapeutics since its foundation in September 2018 to $84.5M. As part of this Series A round, a new Dutch company, Prilenia Therapeutics B.V. has been formed. The new company will hold the Israeli subsidiary company Prilenia Neurotherapeutics Ltd.
More information can be found here: https://www.prilenia.com/copy-of-18-september-2019-pr
Edwin Liem, Martina Priekaar and Anna Zhu.